#United States #Cleveland #Chronic Pain #Neuronoff #Injectrode

Neuronoff Secures Financial Backing for Pain Relief Breakthrough

Neuronoff, Inc., a pioneering name in the medical device field focused on innovative pain management solutions, has successfully closed an impressive $4.5 million financing round. This funding is intended to propel its cutting-edge Injectrode platform towards FDA approval and facilitate its upcoming commercial launch, while fulfilling the urgent need for effective treatments for chronic pain.

The Injectrode platform represents a significant leap forward in neuromodulation technology, designed to deliver pain relief without the complications associated with traditional surgical procedures. With a focus on minimally invasive solutions, the Injectrode system utilizes the smallest diameter implants currently available, measuring just 1mm, which is roughly half the size of a grain of rice. This innovative device is administered via an 18-gauge needle, completely replacing the bulky one- to two-inch incisions typically required for chronic pain neurostimulation therapies.

One of the most appealing aspects of the Injectrode is its potential as a drug-free alternative for patients suffering from chronic pain. By minimizing surgical cuts, the technology promises to eliminate visible scars and substantially reduce the costs often associated with conventional neuromodulation systems. CEO Manfred Franke remarked, "This funding validates our investors' confidence in bringing elegant, needle-based neuromodulation to future patients. We aim to offer effective chronic pain treatments without opioids, without surgery, and without scars."

The funding will also support scaling up production to meet an anticipated demand, planning to manufacture 1,000 units annually. A limited roll-out is expected in the United States targeting various specialists including interventional pain physicians, spinal surgeons, and podiatrists, slated for 2026.

In addition to being an efficient treatment option, the Injectrode platform has been designed in a way that drastically reduces healthcare costs by 50% or more compared to traditional neuromodulation therapies. This innovation could leverage earlier insurance authorizations during the treatment timeline, significantly enhancing access for patients. Franke emphasized that optimizing the Injectrode for codes applicable to CMS (Centers for Medicare & Medicaid Services) should also alleviate some administrative burdens on healthcare providers, enabling them to focus on patient care rather than handling negotiations with insurers.

The preclinical results point toward a promising safety profile and functionality, with the Injectrode having demonstrated its efficacy in a first-in-human trial for chronic lower back pain. None of the patients experienced serious adverse events, ensuring confidence in the product’s future applications across a wider therapeutic scope beyond merely pain management.

In a strategic move, Neuronoff has launched a wholly-owned subsidiary dedicated to commercializing the Injectrode for an undisclosed indication that affects approximately 16 million U.S. adults, a critical group that stands to benefit from such innovations. Further details about the Injectrode and its potential impacts will be announced during the North American Neuromodulation Society’s (NANS) Annual Meeting in January 2026 in Las Vegas, an event highly anticipated by industry insiders.

As Neuronoff continues on this promising journey, their vision aligns strongly with the overarching goal of providing effective treatments for chronic conditions while bridging the gap between advanced medical technology and wider accessibility for patients. The company's headquarters is based in Cleveland, Ohio, where they are committed to developing injectable neuromodulation solutions designed to eliminate traditional surgical barriers. For more information on Neuronoff and updates on the Injectrode platform, interested parties can visit their official website at www.neuronoff.com.